1. Aspirin in Cardioprevention:

3. The Role of Aspirin Today

4. Our Good Old Friend Aspirin

5. Earlier Primary Prevention Trials: Aspirin Favored for Serious Vascular Events

6. Physicians' Health Study

7. Contemporary Aspirin Clinical Trials for Primary Prevention

8. Risk Factors for Primary CVD Prevention

9. USPSTF 2016 Statement of Aspirin Use

10. Aspirin Pharmacology and Biological Effect

11. ARRIVE Study Design

12. ARRIVE Patient Enrollment Criteria

13. ARRIVE Results

14. ARRIVE Results (cont)

15. Primary Prevention Trials With Aspirin in Diabetic Patients

16. ASCEND Study Design

17. ASCEND Results

18. Platelet Activity in Diabetic Patients and the Potential Role of Aspirin

19. Aspirin Recommendations for Diabetic Patients

20. Bleeding Is Not New News

21. COMPASS Trial

22. COGENT Trial: Optimization of GI Events

23. Existing Treatment Strategies for Prevention of MACE

24. What Do These New Trials Tell Us?

25. Regular Aspirin Use and Cancer Risk

26. Duration of Aspirin Use and CRC Risk

27. ASPREE Study Design

28. ADAPTABLE Study Design

29. Conclusion

30. Abbreviations

31. Abbreviations (cont)

32. Abbreviations (cont)